MedTech News
Stereotaxis Magic ablation catheter is now CE mark approved
Stereotaxis (NYSE:STXS) said today that it has secured CE mark approval for its Magic robotically-navigated magnetic ablation catheter.
Experimental drug speeds up myelin repair, restoring vision in mice
Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other neurological conditions that damage neurons.
Light-activated ink developed to remotely control cardiac tissue to repair the heart
Researchers from Mass General Brigham and collaborating institutions have developed a non-invasive approach to manipulate cardiac tissue activity by using light to stimulate an innovative ink incorporated into bioprinted tissue.
Proof-of-concept study dissolves clusters of breast cancer cells to prevent metastases
In a study, which has been published in Nature Medicine, a team of researchers from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, shows a new, promising approach
A new vaccine approach could help combat future coronavirus pandemics
The nanoparticle-based vaccine shows promise against many variants of SARS-CoV-2, as well as related sarbecoviruses that could jump to humans.
Saluda Medical Receives FDA Approval for First Automated Programming Platform in SCS
MINNEAPOLIS, Jan. 23, 2025 /PRNewswire/ — Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced United States (U.S.) Food & Drug Administration (FDA) approval for its biomarker-based, automated patient programming platform in spinal cord stimulation (SCS), representing a significant advancement for SCS therapy.
Blackrock Neurotech arrays used in BCI that enables finger-based control using only thought
Blackrock Neurotech announced that researchers used its microelectrode arrays to develop a high-performance brain-computer interface (BCI).
L&C Bio Secures World’s First NMPA Approval for ‘MegaDerm Plus’ in China
SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ — L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China’s National Medical Products Administration (NMPA) for its acellular dermal matrix, “MegaDerm Plus.”